证券之星消息，11月20日中药板块较上一交易日下跌0.21%，康惠股份领跌。当日上证指数报收于 3931.05，下跌0.4%。深证成指报收于12980.82，下跌0.76%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300391 | *ST长药 | 2.83 | 19.92% | 76.39万 | | 1.97亿 | | 600080 | 金花股份 | 69'8 | 7.15% | 57.74万 | | 5.05亿 | | 600222 | 太龙药业 | 7.44 | 3.33% | 34.42万 | | 2.52亿 | | 002317 | 众生药业 | 23.28 | 2.37% | 107.55万 | | 24.58亿 | | 600771 | 广言沅 | 19.48 | 1.51% | 7.15万 | | 1.39亿 | | 600285 | 羚锐制药 | 22.45 | 1.31% | 5.11万 | | 1.14亿 | | 000423 ...

Market Overview - The Chinese medicine sector rose by 0.39% on November 12, with Zhongsheng Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] Top Performers - Zhongsheng Pharmaceutical (002317) closed at 23.38, up 10.02% with a trading volume of 1.3442 million shares [1] - Panlong Pharmaceutical (002864) closed at 35.64, up 10.00% with a trading volume of 162,700 shares [1] - Te Yi Pharmaceutical (002728) closed at 13.41, up 5.09% with a trading volume of 1.6884 million shares [1] - Other notable gainers include Jiu Zhi Tang (000989) up 4.99% and Jin Hua Co. (600080) up 4.93% [1] Underperformers - Yiling Pharmaceutical (002603) closed at 20.01, down 2.25% with a trading volume of 668,600 shares [2] - Weikang Pharmaceutical (300878) closed at 28.72, down 1.98% with a trading volume of 99,900 shares [2] - Kangmei Pharmaceutical (600518) closed at 2.09, down 1.42% with a trading volume of 2.9625 million shares [2] Capital Flow - The Chinese medicine sector saw a net inflow of 196 million yuan from institutional investors, while retail investors contributed a net inflow of 80.93 million yuan [2] - Speculative funds experienced a net outflow of 277 million yuan [2] Individual Stock Capital Flow - Zhongsheng Pharmaceutical had a net inflow of 4.03 billion yuan from institutional investors, but a net outflow of 2.13 billion yuan from speculative funds [3] - Tongrentang (600085) saw a net inflow of 1.22 billion yuan from institutional investors, with a net outflow of 508.17 million yuan from speculative funds [3] - Other stocks like Pian Zai Huang (600436) and Dong E E Jiao (000423) also experienced significant net inflows from institutional investors [3]

流感概念反复活跃，特一药业2连板，博晖创新20cm涨停，盘龙药业触及涨停，众生药业、哈三联、金 花股份跟涨。 ...

Core Viewpoint - Jinhua Co., Ltd. is a well-known pharmaceutical company in China, established in 1996 and listed in 1997, with a strong focus on drug research, production, and sales, but its revenue and net profit rankings are significantly lower than industry leaders [1][2]. Group 1: Business Performance - For Q3 2025, Jinhua's revenue was 384 million yuan, ranking 59th out of 69 in the industry, significantly lower than the top company, Baiyunshan, with 61.61 billion yuan, and the industry average of 375.5 million yuan [2]. - The net profit for the same period was 34.24 million yuan, ranking 47th out of 69, again far below the leading company, Yunnan Baiyao, which reported 4.789 billion yuan, and the industry average of 447 million yuan [2]. Group 2: Financial Ratios - Jinhua's debt-to-asset ratio was 19.09% in Q3 2025, up from 18.29% the previous year, which is significantly lower than the industry average of 32.81%, indicating a lower debt burden [3]. - The gross profit margin for Q3 2025 was 76.55%, slightly down from 77.98% year-on-year, but still above the industry average of 52.44%, reflecting strong product profitability [3]. Group 3: Executive Compensation - The chairman, Xing Yajiang, received a salary of 1.1203 million yuan in 2024, an increase of 576,000 yuan from 2023 [4]. - The general manager, Han Zhuojun, earned 809,800 yuan in 2024, up by 113,200 yuan from the previous year [4]. Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 2.22% to 20,100, while the average number of circulating A-shares held per account increased by 2.27% to 18,600 [5].

Core Viewpoint - Jinhua Co., Ltd. (600080.SH) reported its Q3 2025 results, indicating a decrease in institutional ownership compared to the previous quarter [1] Institutional Ownership - As of October 29, 2025, two institutional investors disclosed holdings in Jinhua Co., Ltd., totaling 20.4263 million shares, which represents 5.47% of the total share capital [1] - The institutional ownership ratio decreased by 0.80 percentage points compared to the previous quarter [1] Public Fund Holdings - In this reporting period, 12 public funds were not disclosed compared to the previous quarter, including notable funds such as: - China Merchants CSI Consumer Leaders Index Enhanced A - Huaxia Dingrong Bond A - Bodao Consumption Smart Navigation A - Guolian SSE Sci-Tech Innovation Board Comprehensive Index Enhanced A - Huiquan Qiyuan Future Mixed Initiation A [1]

Summary of Key Points Core Viewpoint - On October 29, Hangzhou Oxygen Plant Co., Ltd. disclosed an increase in shareholding, while 11 A-share listed companies announced plans for share reductions [1][2]. Group 1: Shareholding Increases - Hangzhou Oxygen Plant received a stake increase from CITIC Financial Assets, raising its holding to 5% [2]. Group 2: Shareholding Reductions - Greenfield Machinery: Shareholder Shao Yutian plans to reduce holdings by no more than 3% [2]. - Jianghua Micro: Shareholder Yin Fuhua intends to reduce holdings by no more than 3% [2]. - Jiuzhou Group: Shareholders plan to collectively reduce holdings by no more than 1.88% [2]. - Guorui Technology: Shareholder Gong Ruiliang plans to reduce holdings by no more than 3% [2]. - Kairun Co., Ltd.: Shareholder Li Zhongren plans to reduce holdings by no more than 1.70% [2]. - Yingjixin: Shareholder plans to transfer 2.9% of company shares through inquiry [2]. - Mindong Electric: Shareholder Provincial Investment Group intends to reduce holdings by no more than 1% [2]. - WuXi AppTec: Shareholders controlled by the actual controller plan to reduce holdings by no more than 2% [2]. - Zhongwei Company: A dedicated repurchase account plans to reduce holdings by no more than 0.33% [2]. - Jinhua Co., Ltd.: Plans to reduce no more than 746.54 million shares that have been repurchased [2]. - Hechuan Technology: Bosch China intends to reduce holdings by no more than 3% [2].

Core Viewpoint - Jinhua Co., Ltd. reported a decline in revenue for Q3 2025, while net profit showed significant growth, indicating a mixed financial performance [1] Financial Performance - The company's operating revenue for Q3 2025 was 143 million yuan, representing a year-on-year decrease of 17.55% [1] - The net profit attributable to shareholders of the listed company was 28.2862 million yuan, which is a year-on-year increase of 32.75% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 18.5622 million yuan, reflecting a substantial year-on-year increase of 152.98% [1]

证券代码：600080 股票简称：金花股份 编号：临 2025-045 金花企业（集团）股份有限公司 第十届董事会第二十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 金花企业（集团）股份有限公司（以下简称"公司"）第十届董事会第二十 三次会议通知于 2025 年 10 月 24 以电子邮件及微信方式发出，会议于 2025 年 10 月 28 日以通讯表决方式召开，应参与表决董事 7 人，实际表决人数 7 人，符 合《公司法》和《公司章程》的有关规定。经讨论表决，会议通过如下决议。 二、董事会会议审议情况 表决结果：同意票 7 票，反对票 0 票，弃权票 0 票 具体内容详见公司同日在上海证券报及上海证券交易所网站（www.sse.com.cn） 披露的《金花企业（集团）股份有限公司 2025 年第三季度报告》。 本议案已经公司第十届董事会审计委员会第十六次会议审议通过。 （二）通过《关于回购股份集中竞价减持计划的议案》 表决结果：同意票 7 票，反对票 0 票，弃权票 0 票 ...

证券代码：600080 证券简称：金花股份 公告编号：2025-044 金花企业（集团）股份有限公司 关于回购股份集中竞价减持计划的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司于 2025 年 10 月 28 日召开第十届董事会第二十三次会议，审议通过了 《关于回购股份集中竞价减持计划的议案》，同意公司根据 2024 年 2 月 23 日披 露的《关于以集中竞价交易方式回购公司股份的回购报告书》（公告编号： 1 2024-009 号）（以下简称"《回购报告书》"）的约定及要求，采用集中竞价交易 方式减持公司已回购的部分股份。本次减持计划具体情况如下： 一、减持主体的基本情况 | 股东名称 | 金花企业（集团）股份有限公司回购专用证券账户 | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 | √否 | | | 直接持股 5%以上股东 | √是 | □否 | | | 董事、监事和高级管理人员 | □是 | √否 | | | 其他：回购专 ...

Financial Performance - The company's operating revenue for the third quarter was ¥142,615,399.97, a decrease of 17.55% compared to the same period last year[4] - The total profit for the quarter was ¥31,401,852.36, representing an increase of 35.31% year-on-year[4] - The net profit attributable to shareholders was ¥28,286,232.43, up 32.75% from the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥18,562,240.03, a significant increase of 152.98%[4] - The basic earnings per share for the quarter was ¥0.0802, reflecting a growth of 38.51% compared to the same period last year[5] - The net profit for the first three quarters of 2025 is CNY 34,237,396.22, an increase from CNY 30,770,165.28 in the same period of 2024, representing a growth of approximately 8.0%[20] - The total comprehensive income attributable to the parent company for the first three quarters of 2025 is CNY 34,481,243.86, compared to CNY 30,770,165.28 in 2024, marking an increase of about 12.0%[20] Cash Flow and Investments - The net cash flow from operating activities for the quarter was ¥23,212,140.36, an increase of 3.90% year-on-year[4] - The net cash flow from operating activities for the first three quarters of 2025 is -CNY 57,721,288.63, compared to -CNY 758,663.64 in 2024, showing a significant decline in cash flow[22] - The company reported an investment cash flow net of -CNY 53,103,754.27 for the first three quarters of 2025, an improvement from -CNY 246,291,188.28 in the same period of 2024[22] - The financing activities generated a net cash flow of CNY 8,371,831.95 in the first three quarters of 2025, contrasting with -CNY 116,065,246.78 in 2024, indicating a recovery in financing[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,956,751,621.65, a decrease of 0.78% compared to the end of the previous year[5] - Cash and cash equivalents as of September 30, 2025, were CNY 235,467,381.44, down from CNY 347,680,977.31 as of December 31, 2024, representing a decrease of 32.23%[13] - Total current assets decreased to CNY 627,234,148.73 as of September 30, 2025, from CNY 782,365,271.63 as of December 31, 2024, a decline of 19.83%[14] - Total liabilities decreased to CNY 373,611,848.21 as of September 30, 2025, from CNY 412,587,405.60 as of December 31, 2024, a reduction of 9.45%[15] - Total assets as of September 30, 2025, were CNY 1,956,751,621.65, slightly down from CNY 1,972,071,163.91 as of December 31, 2024[16] Shareholder Information - The company reported a total of 20,096 common shareholders at the end of the reporting period[11] - The largest shareholder, Xing Boyue, holds 19.63% of the shares, with 73,272,546 shares pledged[11] Research and Development - Research and development expenses increased to CNY 22,330,991.27 in the first three quarters of 2025, compared to CNY 20,283,032.38 in the same period of 2024, reflecting a growth of 10.12%[18] Accounting Standards - The company has not applied new accounting standards for the current reporting period[23]